Jay Skyler
Director/Board Member chez APPLIED THERAPEUTICS, INC.
Fortune : 14 M $ au 31/03/2024
Profil
Jay S.
Skyler is currently the Director at Intarcia Therapeutics, Inc. and the Deputy Director & Professor at the Diabetes Research Institute.
He is also an Independent Director at Applied Therapeutics, Inc. and a Director at Moerae Matrix, Inc. Additionally, he holds the position of Professor at the University of Miami.
In the past, Dr. Skyler served as the Chairman-Study at the National Institute of Diabetes & Digestive & Kidney Diseases and Chairman-Subspecialty Societies Council at the American College of Physicians.
He was also an Independent Director at Amylin Pharmaceuticals, Inc. from 1999 to 2012 and a Director at MiniMed, Inc. Furthermore, he served as an Independent Director at DexCom, Inc. from 2002 to 2023.
Dr. Skyler was a Director at Aerami Therapeutics, Inc. from 2013 to 2014 and held the position of Vice President at the International Diabetes Federation.
He also served as the Editor-in-Chief at the American Diabetes Association and was a Member-Examining Board at the American Board of Internal Medicine.
Additionally, he held the role of President at the Southern Society for Clinical Investigation.
Dr. Skyler completed his undergraduate studies at The Pennsylvania State University and obtained his doctorate from Sidney Kimmel Medical College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DEXCOM, INC.
0,03% | 18/05/2023 | 103 348 ( 0,03% ) | 14 M $ | 31/03/2024 |
| 06/06/2023 | 20 000 ( 0,02% ) | 136 000 $ | 31/03/2024 |
Postes actifs de Jay Skyler
| Sociétés | Poste | Début |
|---|---|---|
| APPLIED THERAPEUTICS, INC. | Director/Board Member | 01/04/2019 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Director/Board Member | 19/09/2017 |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services University of Miami (Florida) is a private research university with students from around the world that is focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. The university was founded in 1925 and it is headquartered in Coral Gables, FL. | Corporate Officer/Principal | 01/01/2004 |
| Diabetes Research Institute | Corporate Officer/Principal | 01/01/1976 |
Moerae Matrix, Inc. /Nj/
 Moerae Matrix, Inc. /Nj/ Miscellaneous Commercial ServicesCommercial Services Moerae Matrix, Inc. is a biotechnology company based in Morristown, NJ. Moerae Matrix, Inc. develops novel therapies as a biotechnology company. The company was founded by Cynthia Lander, who has been the CEO since incorporation. | Director/Board Member | - |
Anciens postes connus de Jay Skyler
| Sociétés | Poste | Fin |
|---|---|---|
| DEXCOM, INC. | Director/Board Member | 18/05/2023 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Director/Board Member | 08/08/2012 |
| MiniMed, Inc. | Director/Board Member | 01/01/2001 |
International Diabetes Federation
 International Diabetes Federation Miscellaneous Commercial ServicesCommercial Services The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 160 countries and territories. The private company is based in Brussels, Belgium. The mission of IDF is to promote diabetes care, prevention, and a cure worldwide. IDF advocates for people with diabetes and works towards its mission by collaborating with national diabetes associations, healthcare professionals, and policymakers. Founded in 1950, IDF represents the interests of the growing number of people with diabetes and those at risk. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░ ░░░ ░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░ | - |
Formation de Jay Skyler
| The Pennsylvania State University | Undergraduate Degree |
| Sidney Kimmel Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DEXCOM, INC. | Health Technology |
| APPLIED THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
| MiniMed, Inc. | Health Technology |
International Diabetes Federation
International Diabetes Federation Miscellaneous Commercial ServicesCommercial Services The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 160 countries and territories. The private company is based in Brussels, Belgium. The mission of IDF is to promote diabetes care, prevention, and a cure worldwide. IDF advocates for people with diabetes and works towards its mission by collaborating with national diabetes associations, healthcare professionals, and policymakers. Founded in 1950, IDF represents the interests of the growing number of people with diabetes and those at risk. | Commercial Services |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
American Diabetes Association
 American Diabetes Association Miscellaneous Commercial ServicesCommercial Services American Diabetes Association provides diabetes related medical services. It funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The company was founded in 1940 and is headquartered in Alexandria, VA. | Commercial Services |
American Board of Internal Medicine
 American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services The American Board of Internal Medicine operates as a self-appointed physician evaluation organization. The private company is based in Philadelphia, PA. The CEO of the company is Richard J. Baron. | Commercial Services |
| National Institute of Diabetes & Digestive & Kidney Diseases | Government |
| Southern Society for Clinical Investigation | |
| Diabetes Research Institute | |
Aerami Therapeutics, Inc.
 Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerami Therapeutics, Inc. develops inhaled insulin products to treat diabetes patients. Its product Dance 501 is designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few comfortable breaths. The company was founded by John Stuart Patton in February 9, 2009 and is headquartered in Durham, NC. | Health Technology |
American College of Physicians
 American College of Physicians Miscellaneous Commercial ServicesCommercial Services The American College of Physicians operates as a medical-specialty organization. The non-profit company is based in Philadelphia, PA. Darilyn V. Moyer has been the CEO of the company since 2016. | Commercial Services |
Moerae Matrix, Inc. /Nj/
Moerae Matrix, Inc. /Nj/ Miscellaneous Commercial ServicesCommercial Services Moerae Matrix, Inc. is a biotechnology company based in Morristown, NJ. Moerae Matrix, Inc. develops novel therapies as a biotechnology company. The company was founded by Cynthia Lander, who has been the CEO since incorporation. | Commercial Services |
